SPRY4 and cancer: Reduction of SPRY4 expression, for example, increases cancer stem cell properties in MDA-MB-231 cells, while reduced expression of FOXA1 and GATA3 by inhibiting the mitogen-and stress-activated protein kinase (MSK1) enhances the metastatic progression of ER + breast cancer.